Blood Advances

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease
Blood Advances - Tập 6 - Trang 5317-5326 - 2022
Ferdows Atiq, Jessica Heijdra, Fleur Snijders, Johan Boender, Eva Kempers, Waander L. van Heerde, Dominique P.M.S.M. Maas, Sandy Krouwel, Selene C. Schoormans, Joke de Meris, Saskia E.M. Schols, Karin P.M. van Galen, Johanna G. van der Bom, Marjon H. Cnossen, Karina Meijer, Karin Fijnvandraat, Jeroen Eikenboom, Frank W.G. Leebeek
Abstract Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene variant is associated with desmopressin response in type 1 VWD, the association between variants in the VWF gene and desmopressin response is not yet fully understood. Our primary aim was to compare desmopressin resp... hiện toàn bộ
Fundamentals of immunology for understanding immunotherapy for lymphoma
Blood Advances - Tập 4 - Trang 5863-5867 - 2020
Stephen M. Ansell
Abstract An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient’s disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immu... hiện toàn bộ
Peripheral blood monocyte count is a dynamic prognostic biomarker in multiple myeloma
Blood Advances - Tập 7 - Trang 482-490 - 2023
Camille V. Edwards, Hamza Hassan, Cenk Yildirim, Grace Ferri, Karina P. Verma, Mara E. Murray Horwitz, Nathanael R. Fillmore, Nikhil C. Munshi
Abstract With the growing knowledge of multiple myeloma (MM) pathobiology and the introduction of novel therapies, risk stratification continues to evolve. Myeloid-derived suppressor cells and tumor-associated macrophages, derived from peripheral blood monocytes, support malignant plasma cell proliferation in the bone marrow. Because peripheral blood absolute monocyte count (AMC) is thought to ref... hiện toàn bộ
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study
Blood Advances - Tập 7 - Trang 414-421 - 2023
Charles T. Quinn, Richard T. Wiedmann, Daniel Jarovsky, Eduardo Lopez-Medina, Hilze M. Rodriguez, Melanie Papa, Gordana Boggio, Qiong Shou, Ron Dagan, Peter Richmond, Kristen Feemster, Richard McFetridge, Gretchen Tamms, Robert Lupinacci, Luwy Musey, Kara Bickham
AbstractSickle cell disease (SCD) is an inherited red blood cell disease that results in a multitude of medical complications, including an increased risk of invasive disease caused by encapsulated bacteria, such as Streptococcus pneumoniae. Pneumococcal vaccines have contributed to a significant reduction in pneumococcal disease (PD) in children and adults, including those with SCD. This phase 3 ... hiện toàn bộ
American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America
Blood Advances - Tập 6 - Trang 3636-3649 - 2022
Ignacio Neumann, Ariel Izcovich, Ricardo Aguilar, Guillermo León Basantes, Patricia Casais, Cecilia C. Colorio, María Cecilia Guillermo Esposito, Pedro P. García Lázaro, Jaime Pereira, Luis A. Meillon-García, Suely Meireles Rezende, Juan Carlos Serrano, Mario L. Tejerina Valle, Felipe Vera, Lorena Karzulovic, Gabriel Rada, Holger J. Schünemann
Abstract Background: Venous thromboembolism (VTE) is a common disease in Latin American settings. Implementation of international guidelines in Latin American settings requires additional considerations. Objective: To provide evidence-based guidelines about VTE prevention for Latin American patients, clinicians, and decision makers. Methods: We used the GRADE ADOLOPMENT method to adapt recommendat... hiện toàn bộ
Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome
Blood Advances - Tập 7 - Trang 5799-5811 - 2023
Francesca Guijarro, Monica López-Guerra, Jordi Morata, Alex Bataller, Sara Paz, Josep Maria Cornet-Masana, Antònia Banús-Mulet, Laia Cuesta-Casanovas, Josep Maria Carbó, Sandra Castaño-Díez, Carlos Jiménez-Vicente, Albert Cortés-Bullich, Ana Triguero, Alexandra Martínez-Roca, Daniel Esteban, Marta Gómez-Hernando, José Ramón Álamo Moreno, Irene López-Oreja, Marta Garrote, Ruth M. Risueño
Abstract Germ line predisposition in acute myeloid leukemia (AML) has gained attention in recent years because of a nonnegligible frequency and an impact on management of patients and their relatives. Risk alleles for AML development may be present in patients without a clinical suspicion of hereditary hematologic malignancy syndrome. In this study we investigated the presence of germ line variant... hiện toàn bộ
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study
Blood Advances - Tập 3 - Trang 1815-1825 - 2019
M. O'Dwyer, R. Henderson, S.D. Naicker, M.R. Cahill, P. Murphy, V. Mykytiv, J. Quinn, C. McEllistrim, J. Krawczyk, J. Walsh, E. Lenihan, T. Kenny, A. Hernando, G. Hirakata, I. Parker, E. Kinsella, G. Gannon, A. Natoni, K. Lynch, A.E. Ryan
Abstract Daratumumab (DARA) has shown impressive activity in combination with other agents for the treatment of multiple myeloma (MM). We conducted a phase 1b study to assess the safety and preliminary efficacy, as well as potential mechanisms of action, of DARA (16 mg/kg) in combination with a weekly schedule of subcutaneous bortezomib (1.3-1.5 mg/m2), cyclophosphamide (150-300 mg/m2), and dexame... hiện toàn bộ
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells
Blood Advances - Tập 4 - Trang 87-99 - 2020
Karen Phaik Har Lim, Paul Milne, Michael Poidinger, Kaibo Duan, Howard Lin, Naomi McGovern, Harshal Abhyankar, Daniel Zinn, Thomas M. Burke, Olive S. Eckstein, Rikhia Chakraborty, Amel Sengal, Brooks Scull, Evan Newell, Miriam Merad, Kenneth L. McClain, Tsz-Kwong Man, Florent Ginhoux, Matthew Collin, Carl E. Allen
Key PointsTranscriptional profile of LCH CD1a+CD207+ DCs is most closely related to that of CD1c+ mDCs in the blood. Lineage tracing with BRAFV600E and HLA-DQB2 expression supports CD1c+ mDCs as precursors to LCH CD1a+CD207+ DCs.
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
Blood Advances - Tập 2 - Trang 1386-1392 - 2018
Kristina Drott, Hans Hagberg, Karin Papworth, Thomas Relander, Mats Jerkeman
Key Points This trial evaluates addition of the histone deacetylase inhibitor valproate to standard R-CHOP therapy in DLBCL. Addition of valproate to R-CHOP is a promising strategy in DLBCL, but auditory side effects warrant monitoring.
4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
Blood Advances - Tập 6 - Trang 1879-1894 - 2022
Julian Swatler, Laura Turos-Korgul, Marta Brewinska-Olchowik, Sara De Biasi, Wioleta Dudka, Bac Viet Le, Agata Kominek, Salwador Cyranowski, Paulina Pilanc, Elyas Mohammadi, Dominik Cysewski, Ewa Kozlowska, Wioleta Grabowska-Pyrzewicz, Urszula Wojda, Grzegorz Basak, Jakub Mieczkowski, Tomasz Skorski, Andrea Cossarizza, Katarzyna Piwocka
AbstractChronic and acute myeloid leukemia evade immune system surveillance and induce immunosuppression by expanding proleukemic Foxp3+ regulatory T cells (Tregs). High levels of immunosuppressive Tregs predict inferior response to chemotherapy, leukemia relapse, and shorter survival. However, mechanisms that promote Tregs in myeloid leukemias remain largely unexplored. Here, we identify leukemic... hiện toàn bộ
Tổng số: 1,527   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10